Anavex Drug Delivers Positive Phase 2 Schizophrenia Results
ANAVEX3-71 met its primary endpoint in a placebo-controlled Phase 2 study in adults with schizophrenia on stable antipsychotic therapy,...
Promising VQ-101 Trial Data Offers New Hope for Parkinson’s
VQ-101 delivered more than 70% activation of lysosomal glucocerebrosidase in GBA-Parkinson’s patients after 28 days of once-daily dosing, exceeding...
ALX Oncology Links CD47 to HER2+ Gastric Cancer Outcomes
ALX Oncology will present updated Phase 2 data from ASPEN-06, indicating that tumor CD47 overexpression may predict response to...
BriaCell to Present New Bria-OTS+™ Preclinical Data at SITC
BriaCell will debut preclinical data for Bria-OTS+, an off-the-shelf cancer vaccine platform that aims to combine trained innate immunity...
Vielight Summit: Groundbreaking New Tech For Meditation
No new clinical efficacy endpoints were disclosed. Vielight introduced a meditation-specific protocol within its Neuro Pro photobiomodulation device and...
Camp4’s Pioneering SYNGAP-1 Drug Enters Toxicology Studies
CAMP4 Therapeutics has begun GLP toxicology studies for CMP-SYNGAP-01, an intrathecally delivered antisense oligonucleotide designed to upregulate SYNGAP1 expression...
Radiopharm Trial To Accelerate After Positive DSMC Review
After completing the initial 30 mCi cohort with acceptable safety, pharmacokinetics, and biodistribution, the Phase 1 HEAT study of...
New AML Clinical Trial Targets Dual NPM1 & FLT3 Mutations
Kura Oncology and Kyowa Kirin have dosed the first patient in a new cohort of the Phase 1b KOMET-007...
Comphya Implants First CaverStim Device in U.S. Pilot Study
A 20-patient, single-site U.S. pilot has begun enrolling at Johns Hopkins under an FDA IDE to evaluate the safety...
Nuwellis: 92% Survival in Kids with Kidney Injury, Failure
Topline: In a multicenter registry of 91 critically ill pediatric patients treated with the Aquadex ultrafiltration system, 92% survived...